TechnologyPatent OppositionCompetitive Analysis

Explore the competitive field of Mixed Drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in Mixed Drugs technology and learn how to protect your intellectual property.

Get Patent Opposition Report for Mixed Drugs

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Report

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the Mixed Drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the Mixed Drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Aug 21, 2025
Patent NumberTitleApplicantOpposition DateOpposition Name

Get alerts on new patent oppositions in the Mixed Drugs industry

New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 23, 2025HAMM & WITTKOPP
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 22, 2025TEVA PHARMACEUTICALS
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 21, 2025ELPEN PHARMACEUTICAL
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 18, 2025EGIS
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 16, 2025DR SCHON
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 14, 2025SYNTHON
Use Of Cannabinoids In The Treatment Of Seizures Associated With Lennox-Gastaut SyndromeJAZZ PHARMACEUTICALS RESEARCH UKJul 8, 2025KRAUS & LEDERER PARTGMBB
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 1, 2025GENERICS UK
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJun 25, 2025ZENTIVA KS
Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor PertuzumabF HOFFMANN LA ROCHEJun 18, 2025BRAND MURRAY FULLER

To stay ahead in the competitive Mixed Drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the Mixed Drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Aug 21, 2025
Patent NumberGrant DateTitleApplicantTotal Oppositions
Apr 14, 2021Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGY22
Oct 23, 2024New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTIS17
Oct 11, 2023New UseNOVARTIS16
Mar 10, 2021Novel Antitumoral Use Of CabazitaxelSANOFI MATURE13
Sep 14, 2022Therapeutic Uses Of EmpagliflozinBOEHRINGER INGELHEIM10
May 15, 2019Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor PertuzumabF HOFFMANN LA ROCHE9
Dec 13, 2023Combinations Of Dolutegravir And Lamivudine For The Treaetment Of Hiv InfectionVIIV HEALTHCARE9
Oct 30, 2019New UseNOVARTIS9
Dec 11, 2019Methods Of Treating Hepatic EncephalopathySALIX PHARMACEUTICALS8
Oct 9, 2019Crispr-Based Genome Modification And RegulationSIGMA ALDRICH8